Business Context and Reporting Period
Company: AYTU BIOSCIENCE, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 27, 2016
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Details
- Initial Investment: $500,000 for 133,690 shares of common stock purchased by Lincoln Park Capital Fund, LLC ("Lincoln Park").
- Total Commitment: Lincoln Park is obligated to purchase up to an additional $10.0 million in shares over a 36-month period, subject to conditions.
- Purchase Mechanism:
- Regular Purchases: Up to 10,000 shares per business day (max $500,000 per transaction).
- Accelerated Purchases: Available if the closing sale price meets specific threshold criteria.
- Ownership Limit: Purchases are capped at 4.99% of outstanding shares (increasable to 9.99% with notice).
- Commitment Fee: 52,500 shares of common stock issued to Lincoln Park upon signing.
- Transaction Costs: $100,000 paid immediately to financial advisors (Joseph Gunnar & Co., LLC and Fordham Financial Management, Inc.), with an additional $100,000 payable upon the earlier of six months or registration statement effectiveness.
- Use of Proceeds: General corporate purposes and working capital requirements.
Material Changes Versus Prior Period
This filing reports a discrete corporate event rather than periodic financial performance. Consequently, there are no comparative revenue, profit, or cash flow metrics provided in this document. The material change is the establishment of a new equity financing facility with a $10.0 million potential capacity.
Guidance, Outlook, and Risks
- Management Commentary: Actual sales under the agreement depend on market conditions, trading price, and management's determination of funding needs. The company retains the right to terminate the agreement at any time without penalty.
- Investor Obligations: Lincoln Park is obligated to purchase shares when directed by the company but has no right to require sales. Lincoln Park has covenanted against short selling or hedging the company's stock.
- Risks and Contingencies:
- Future funding is contingent on the effectiveness of a registration statement filed with the SEC.
- Purchase prices for future shares will be based on prevailing market prices at the time of sale.
- Securities sold in the initial transaction were unregistered and may not be resold in the U.S. absent registration or an exemption.
Key Facts for Investor Verification
- Verify the effectiveness of the registration statement required to unlock the full $10.0 million funding capacity.
- Monitor the dilution impact of the initial 133,690 shares and the 52,500 commitment fee shares.
- Track the company's utilization of the facility, as future sales are at the company's sole discretion.
- Confirm the status of the additional $100,000 advisory fee obligation.